Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL

Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL

Our previous clinical study achieved complete remission (CR) rates of >90% following chimeric antigen receptor T cells targeting CD19 (CART19) treatment of refractory/relapsed B cell acute lymphoblastic leukemia (r/r B-ALL); however, the influence of the leukemia burden in peripheral blood (PB) b...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Biping Deng, Jing Pan, Zhaoli Liu, Shuangyou Liu, Yunlong Chen, Xiaomin Qu, Yu'e Zhang, Yuehui Lin, Yanlei Zhang, Xinjian Yu, Zhongxin Zhang, Xuansha Niu, Rong Luan, Ming Ma, Xiaomei Li, Tingting Liu, Xi'ai Wu, Huan Niu, Alex H. Chang, Chunrong Tong
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
CAR-T cells
CART19
B-cell acute lymphoblastic leukemia
PB blasts
leukemia burden in peripheral blood
time of apheresis
Genetics
QH426-470
Cytology
QH573-671
Acceso en línea:https://doaj.org/article/8a5d1e95aae845aaab269d3ee1c2bab7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/8a5d1e95aae845aaab269d3ee1c2bab7

Ejemplares similares